← Compound Library

CJC-1295 (no DAC)

GHRH Analog

Also known as: Modified GRF(1-29) · Mod GRF 1-29 · Sermorelin analog

A stabilized Growth Hormone-Releasing Hormone analog with a 30-minute half-life, producing clean physiological GH pulses without the extended clearance of DAC-modified versions.

Typical Dose

100 mcg per injection, 1–3x daily (paired with Ipamorelin)

Route

Subcutaneous injection

Cycle

12–24 weeks

Half-life

~30 minutes

Storage

Reconstituted: 2–8°C, use within 30 days. Lyophilized: room temp or freezer.

Overview

CJC-1295 (no DAC) is a modified version of the first 29 amino acids of Growth Hormone-Releasing Hormone, with four amino acid substitutions that extend its half-life from 7 minutes (native GHRH 1-29) to approximately 30 minutes. Unlike CJC-1295 with DAC, it does not bind albumin & therefore does not produce a continuous multi-day GH elevation.

It acts on pituitary GHRH receptors to amplify the natural GH pulse rather than replacing it. When combined with a GHRP (such as Ipamorelin), the two peptides act on different receptor systems to produce synergistic GH release. This GHRH + GHRP combination is the foundation of most GH secretagogue protocols.

The no-DAC formulation is preferred for pulse-based protocols because its 30-minute half-life matches the pharmacokinetics of GHRPs & allows timed, physiological-style GH pulses that do not suppress endogenous GH production.

Quick Start Guide

1

Reconstitute with 2 mL bacteriostatic water per 2 mg vial (1000 mcg/mL).

2

Inject 100 mcg (0.1 mL) subcutaneously alongside Ipamorelin 200 mcg, 30 minutes before sleep.

3

Avoid food for 2 hours before the injection; insulin suppresses GH release.

4

This is best used as part of the Ipamorelin + CJC-1295 stack rather than as a standalone.

Research Indications

GH pulse amplification (as part of GHRH/GHRP stack)

Most Effective

When combined with Ipamorelin or another GHRP, CJC-1295 (no DAC) produces a synergistic GH pulse through complementary pituitary receptor activation.

Anti-aging & body composition

Effective

Downstream IGF-1 elevation from repeated GH pulses supports lean mass, fat metabolism, collagen synthesis, & recovery.

Research Protocols

Classic GHRH/GHRP stack

12–24 weeks

Dose

100 mcg CJC-1295 + 200 mcg Ipamorelin

Frequency

Once daily pre-sleep (or 2–3x daily)

Route

SubQ abdomen — inject both peptides in the same syringe or back-to-back

Peptide Interactions

IpamorelinSynergistic

The canonical GHRH/GHRP stack. Acts on complementary receptor systems for synergistic GH pulse amplification.

GHRP-2Synergistic

Higher GH output than with Ipamorelin but with more cortisol elevation. Used when maximal GH release is the priority.

Side Effects & Safety

Common

  • Transient water retention
  • Tingling or numbness in extremities
  • Increased hunger

Uncommon

  • Headache
  • Joint pain (from water retention & rapid IGF-1 increase)

When to Stop

  • Active malignancy
  • Signs of allergic reaction
  • Diabetic patients should monitor glucose carefully

How to Reconstitute

1

Swab the vial stopper with alcohol.

2

Draw 2 mL bacteriostatic water into a syringe.

3

Inject slowly down the inner wall of the vial.

4

Swirl gently until dissolved. Refrigerate at 2–8°C.

Dosing math: 2 mL BAC water per 2 mg vial gives 1000 mcg/mL. For 100 mcg dose: draw 0.1 mL.

Quality Indicators

Good — use as normal

  • Clear, colorless solution

Acceptable

  • Very slight cloudiness clearing immediately on swirl

Discard immediately

  • Persistent cloudiness
  • Discoloration

What to Expect

Week 1–2

GH pulses are immediate but IGF-1 takes 2–4 weeks to measurably rise. Sleep quality improvement often reported first.

Week 3–6

IGF-1 elevated, recovery & body composition changes begin.

Week 7–16

Sustained body composition changes: lean mass increase, fat reduction. Skin & connective tissue quality improvements.

Community Insights

Self-reported. Reflects user experience, not clinical outcomes.

Research References

Stimulation of growth hormone secretion by growth hormone-releasing hormone & its analogs

Endocrine Reviews · 1995

Comprehensive review of GHRH analogs including the modifications used in CJC-1295, covering pituitary receptor pharmacology & GH release kinetics.

Verify what you have

Information on this page applies to pharmaceutical-grade peptides. Purity & identity of research-grade products vary. Certipep provides independent ESI-TOF-MS & HPLC analysis with a signed analytical report.

Submit a sample